How to Inject Wegovy: Devices, Sites, and What the Label Says

Wegovy is injected under the skin (subcutaneously) in the abdomen, thigh, or upper arm, once a week on the same day each week, at any time of day, with or without meals ^[1]. The exact hand steps, though, depend on which of the three Wegovy injection devices you were given: a single-dose pen, a single-dose syringe, or a Wegovy FlexTouch pen. Device-specific details — priming, pinching, hold times, and storage durations — appear in each product’s Instructions for Use rather than in the prescribing information highlights ^[1]. The PI directs readers to section 17, Patient Counseling Information, and to the Medication Guide ^[1]. For the handling steps for your specific device, use the Instructions for Use that came in your own carton, and ask your pharmacist or prescriber if anything is unclear.

The prescribing information (PI) for Wegovy, revised 06/2026, lists the approved devices, the injection sites, the dosing schedule, and the safety warnings ^[1]. If your device does not behave the way its Instructions for Use describes, that is a question for your pharmacist or prescriber.

Which Wegovy device was I given, and does it change the steps?

Yes, the device changes the steps. Wegovy injection comes in three device types, plus an oral tablet form that is not injected at all ^[1].

Device	Strengths listed in the label	Notes
Single-dose pen	0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, 7.2 mg/0.75 mL (Wegovy HD)	Listed as a single-dose pen [1]
Single-dose syringe	0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL	Listed as a single-dose syringe [1]
Wegovy FlexTouch pen	9.6 mg/3 mL (3.2 mg/mL)	Single-patient-use pen that delivers four 2.4 mg/0.75 mL doses [1]
Tablets	1.5 mg, 4 mg, 9 mg, 25 mg	Taken by mouth, not injected [1]

The single-dose pen and the single-dose syringe contain one dose each, per the label’s dosage forms list ^[1]. The FlexTouch pen is different: it holds 9.6 mg/3 mL of solution and delivers four separate 2.4 mg/0.75 mL doses from the same pen, so it is used across multiple weeks rather than for one injection ^[1]. The label also carries a warning that names the FlexTouch specifically: warning 5.11, “Never Share WEGOVY FlexTouch Between Patients, even if the needle is changed,” added 06/2026 ^[1].

The 7.2 mg strength is Wegovy HD, a higher dose approved by the FDA on March 19, 2026, for adults who have tolerated the 2.4 mg dosage for at least 4 weeks and for whom additional weight reduction is clinically indicated ^[5]. In the label’s dosage forms list, the 7.2 mg/0.75 mL strength appears in the single-dose pen entry ^[1].

If you were also prescribed Ozempic at any point, note that Ozempic is a separate product containing the same molecule, semaglutide, and it comes in its own multi-dose pens and single-dose prefilled syringes, with its own labeling and instructions ^[2].

Where on my body do I inject Wegovy?

The label approves three injection sites: the abdomen, the thigh, and the upper arm ^[1]. The same three sites are specified for Ozempic, which is also semaglutide injection ^[2]. All three sites work because the goal is the same everywhere: getting the medicine into the subcutaneous fat, the layer of tissue between the skin and the muscle ^[4].

Why the fat layer matters comes from the injection-technique literature. When a medicine that is meant for subcutaneous tissue is delivered into muscle instead, absorption becomes faster and more variable ^[4]. That evidence base was built on insulin injections, not GLP-1 trials, so it describes the general physics of subcutaneous injection rather than Wegovy specifically ^[4]. Still, it explains why the label specifies subcutaneous use for all three approved sites.

When do I inject, and how often?

Wegovy injection is given once weekly, on the same day each week, at any time of day, with or without meals ^[1]. You do not need to tie it to a meal or to a particular clock time, but the label does say to keep to the same day each week ^[1].

The dosing schedule in the label starts at 0.25 mg once weekly for 4 weeks, then escalates every 4 weeks according to the schedule in Table 1 of the full prescribing information, until reaching the maintenance dosage ^[1]. The usual recommended maintenance dosage of Wegovy injection is 2.4 mg once weekly, though the full PI lists maintenance dosages that depend on the indication ^[1]. The 7.2 mg Wegovy HD dose is for adults who have tolerated 2.4 mg for at least 4 weeks and need additional weight reduction ^[5].

If you miss a weekly dose, the prescribing information has a dedicated section on missed doses, section 2.4, “Recommendations Regarding Missed Dose(s)” ^[1]. The specifics of what to do are in the full PI, so that question belongs with your prescriber or pharmacist. Do not borrow the missed-dose rule from Ozempic, which says to administer a missed dose within 5 days; that is a different product’s label ^[2].

What angle should I inject at, and should I pinch the skin?

Injection angle and skinfold technique are device-specific details, so how to position and use your device is covered in the Instructions for Use that came with it ^[1].

What the broader evidence says comes from insulin injection research. Mean skin thickness across adults is about 2.0 to 2.5 mm, with a 95% confidence interval of 1.3 to 3.3 mm, and skin thickness is remarkably similar across injection sites, sexes, ethnicities, age groups, and BMI categories ^[4]. Subcutaneous fat thickness, on the other hand, varies widely depending on BMI, sex, and injection site, and post-pubertal females average about 5 mm more subcutaneous fat than men at the same site when controlling for BMI ^[4].

That variation is why no single needle length or angle is right for all adults, and this page will not claim one. What the insulin literature does say is that needles that are too long raise the risk of injecting into muscle, and that patients are often taught two workarounds: lifting a skinfold, or angling the needle 45 degrees from the skin ^[4]. Those are insulin-injection teachings, not Wegovy label instructions, so treat them as background ^[4].

The consensus recommendations behind much of this teaching came out of the FITTER workshop (Forum for Injection Technique and Therapy: Expert Recommendations), held in October 2015, and were largely based on a 2014 to 2015 Injection Technique Questionnaire survey of 13,289 insulin-injecting patients across 42 countries ^[4]. Again, that is insulin evidence, not GLP-1 trial data ^[4].

Do I have to rotate injection sites, and what happens if I don’t?

The injection-technique literature gives a strong reason to rotate sites ^[4]. Repeatedly injecting into the same spot is associated with lipohypertrophy, a buildup of fatty tissue under the skin at injection sites. Lipohypertrophy has been shown to affect at least 50% of injecting patients, and improper site rotation and needle reuse are the most common factors associated with it ^[4].

Injecting into an area of lipohypertrophy is not harmless. It reduces absorption and action of the injected medicine, raises postprandial glucose, and greatly increases uptake variability, at least as demonstrated with insulin ^[4]. One more finding worth knowing: inspection of injection sites is not routinely performed by health care professionals or by patients themselves, which is why problems often go unnoticed ^[4]. Since Wegovy gives you three approved sites to work with, abdomen, thigh, and upper arm, asking your prescriber or diabetes educator how to rotate among them is a reasonable question ^{[1] [4]}.

Can a Wegovy pen ever be shared with a family member?

No. The Wegovy label carries a warning, added 06/2026, titled “Never Share WEGOVY FlexTouch Between Patients, even if the needle is changed” ^[1]. The FlexTouch pen is labeled single-patient-use in the dosage forms list ^[1].

Ozempic carries a parallel warning: never share an Ozempic pen between patients, even if the needle is changed ^[2]. The single-dose Wegovy pen and single-dose syringe are listed in the label as single-dose presentations ^[1].

How do I dispose of the used pen, syringe, or needle?

The FDA recommends a two-step process for used needles and other sharps ^[3].

Step 1: place all needles and other sharps in a sharps disposal container immediately after use. This reduces the risk of needle sticks, cuts, and punctures from loose sharps. Keep sharps disposal containers out of reach of children and pets. Do not overfill the container: when it is about three-quarters (3/4) full, move to step 2. Do not reuse sharps disposal containers ^[3].

Step 2: dispose of the full container according to your community’s guidelines, which vary by where you live. Options the FDA lists include ^[3]:

• Drop boxes or supervised collection sites, such as doctors’ offices, hospitals, pharmacies, health departments, medical waste facilities, and police or fire stations; services may be free or have a nominal fee
• Household hazardous waste collection sites, which also commonly accept cleaners, paints, and motor oil
• Mail-back programs for certain FDA-cleared sharps containers, usually for a fee that varies by container size
• Residential special waste pick-up services, where trained handlers collect containers from your home, typically fee-based

For information specific to your state, including what containers can be used, local disposal programs, labeling, securing the lid, and whether containers can go in common trash, call Safe Needle Disposal at 1-800-643-1643 or email info@safeneedledisposal.org ^[3].

If you travel, carry a small, travel-size sharps disposal container in case other options are not available. If flying, check the Transportation Security Administration (TSA) website for current rules, make sure your medicines are labeled with the medicine type and the manufacturer’s name or a drug store label, and bring a letter from your doctor ^[3].

What safety issues tied to injecting should I flag with my prescriber?

Several warnings in the Wegovy label relate to how the drug is used, and they are worth knowing before you start injecting.

Wegovy carries a boxed warning about thyroid C-cell tumors: in rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures, and it is unknown whether Wegovy causes such tumors, including medullary thyroid carcinoma (MTC), in humans. Wegovy is contraindicated in anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and patients should be counseled on the potential risk and on symptoms of thyroid tumors ^[1]. It is also contraindicated in anyone with known hypersensitivity to semaglutide or any of its excipients ^[1].

If you take insulin or an insulin secretagogue (such as a sulfonylurea), concomitant use with Wegovy may increase the risk of hypoglycemia, including severe hypoglycemia, and reducing the dose of the insulin or secretagogue may be necessary. In patients with diabetes, blood glucose should be monitored before starting and during Wegovy treatment ^[1].

The label also lists a limitation of use: concomitant use of Wegovy injection or tablets with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended ^[1].

Tell your healthcare providers about any planned surgeries or procedures. Pulmonary aspiration has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgery or procedures with general anesthesia or deep sedation ^[1].

The most common adverse reactions, reported at 5% or more in adults or pediatric patients aged 12 years and older, include nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss ^[1]. With Wegovy HD specifically, events related to altered skin sensation, including sensitive skin, hyperesthesia, dysesthesia, and paresthesia, were reported by 22% of participants taking 7.2 mg, compared with 6% taking 2.4 mg and 0.3% on placebo ^[5].

To report suspected adverse reactions, contact Novo Nordisk at 1-833-934-6891 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ^[1]. (For Ozempic, a different product, the Novo Nordisk number is 1-888-693-6742 ^[2].)

What can’t this page tell me, and what should I ask a pharmacist or prescriber?

The device-specific handling steps are the big gap. Whether and how to prime the device, pinch the skin, how long to hold it against the skin, and how long pens or syringes can be stored are covered in each product’s Instructions for Use rather than in the PI highlights ^[1]. For those steps, use the Instructions for Use that came with your device. The PI itself directs readers to section 17, Patient Counseling Information, and to the Medication Guide ^[1].

The label has also been changing. The recent major changes list shows Dosage and Administration revised in 08/2025, 12/2025, and 03/2026, and the “Never Share WEGOVY FlexTouch Between Patients” warning was added 06/2026 ^[1]. Wegovy HD was approved March 19, 2026, and was stated to become available in April through more than 70,000 US pharmacies, select telehealth providers, NovoCare Pharmacy, GoodRx, and other channels ^[5]. Because the label is moving, your pharmacist or prescriber can confirm the current labeling for the device and dose you were dispensed.

Before your first injection, the questions worth bringing to your pharmacist or prescriber include: which device and strength you were dispensed; how to perform the steps in that device’s Instructions for Use; how to rotate among the abdomen, thigh, and upper arm; what to do about a missed weekly dose; and how to get and dispose of a sharps container where you live ^{[1] [3] [4]}.

Sources

1. Novo Nordisk. Wegovy (semaglutide) injection prescribing information.
2. Novo Nordisk. Ozempic (semaglutide) injection prescribing information.
3. US Food and Drug Administration. Best way to get rid of used needles and other sharps.
4. PubMed Central. The injection technique factor: what you don’t know or teach can make a difference.
5. PR Newswire. FDA approves Novo Nordisk’s new Wegovy HD injection, delivering the highest weight loss to date for a Wegovy injection. March 19, 2026.